不同HBV感染转归人群外周血PD-1拷贝数分布研究*

doi:10.3969/j.issn.1672-5069.2019.01.011

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 37-40.doi: 10.3969/j.issn.1672-5069.2019.01.011

不同HBV感染转归人群外周血PD-1拷贝数分布研究^*

李芳, 邹桂舟, 叶珺, 郜玉峰

230601 合肥市安徽医科大学第二附属医院感染病科/肝病科

收稿日期:2018-04-13 出版日期:2019-01-10 发布日期:2019-01-16
作者简介:李芳,女,33岁,医学博士,主治医师。E-mail:84559250@qq.com
基金资助:
*国家自然科学基金资助项目（编号：81273142）

Frequency of PD-1 copy number variation in individuals with hepatitis B viral infection

Li Fang, Zou Guizhou, Gao Yufeng, et al.

Department of Infectious Diseases/Hepatology,Second Affiliated Hospital,AnHui Medical University,Hefei 230601,Anhui Province,China

Received:2018-04-13 Online:2019-01-10 Published:2019-01-16
Contact: Corresponding author:Gao Yufeng, E-mail:aygyf@126.com

摘要/Abstract

摘要： 目的调查HBV感染不同转归人群外周血程序性死亡受体-1（PD-1）基因拷贝数（CN）分布频率的差异。方法在300例HBV感染恢复者、437例慢性乙型肝炎（CHB）、249例肝硬化（LC）和123例肝细胞癌（HCC）患者,采用AccuCopy法检测外周血PD-1基因拷贝数。选择5个可能影响慢性HBV感染结局的指标,即HBeAg滴度、年龄、性别、HBV DNA和PD-1拷贝数,行Logistic回归分析,以发现影响感染结局的指标。结果 HBV感染恢复者、CHB、LC和HCC组外周血PD-1单倍体检出率分别为11.7%、9.6%、6.0%和10.6%,多倍体检出率分别为89.3%、90.4%,94%和89.4%,显示LC组多倍体检出率显著高于HBV感染恢复组或HCC组（P<0.05）;以CHB组作为估计参数,经Logistic回归分析发现年龄和血清HBV DNA载量为影响疾病转归的独立危险因素。结论本研究结果提示影响HBV感染转归的因素还是病毒本身和患者年龄,而外周血PD-1基因拷贝数变异检测的意义还有待于进一步研究。

关键词: 肝癌, 肝硬化, 慢性乙型肝炎, 程序性死亡受体1, 拷贝数变异

Abstract: Objective To explore whether copy number variations （CNVs） of blood programmed cell death-l（PD-1） are associated with outcomes of hepatitis B virus（HBV） infection. Methods 300 convalescent individuals from HBV infection,437 patients with chronic hepatitis B（CHB）,249 patients with liver cirrhosis （LC） and 123 patients with hepatocellular carcinoma（HCC） were recruited in this study,and peripheral blood copy numbers of PD-1 gene were measured by using AccuCopy method. x² tests were used to evaluate the distribution differences of copy number variations（CNVs） of PD-1 in different clinical types of HBV infections. The Logistic regression analysis was used to analyze the independent risk factors for severe outcome of the disease. Results In 1109 samples,the variation range of PD-1 gene copy number was 1 to 3 copies. The haploid rates in convalescent individuals,patients with CHB,with LC and with HCC were 11.7%,9.6%,6.0% and 10.6%,respectively,and the polyploid rates in these four groups were 89.3%,90.4%,94% and 89.4%,demonstrating that there were significant differences between convalescent individuals and patient with LC,or between patient with HCC and with LC（P<0.05）;The Logistic analysis showed that the age and serum HBV DNA loads were the independent risk factors affecting the prognosis of the disease. Conclusions Our results indicate that the patient’s age and serum HBV DNA levels are the risk factors which might determine the prognosis of patients with HBV infection,while what roles the CNVs of PD-1 play in the pathogenesis of hepatitis B viral infection needs further observation.

Key words: Hepatitis B, Liver cirrhosis, Hepatoma, Programmed cell death-l, Copy number variations

李芳, 邹桂舟, 叶珺, 郜玉峰. 不同HBV感染转归人群外周血PD-1拷贝数分布研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 37-40.

Li Fang, Zou Guizhou, Gao Yufeng, et al.. Frequency of PD-1 copy number variation in individuals with hepatitis B viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 37-40.

参考文献

[1] Lavanchy D.Hepatitis B virus epidemiology,disease burden,treatment,and current and emerging prevention and control measures. J Viral Hepat,2004,11(2):97-107.
[2] Mcmahon B J.Epidemiology and natural history of hepatitis B. Semin Liver Dis,2005,25(S1):3-8.
[3] Michielsen PP,Francque SM,Van Dongen JL.Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol,2005,3(1):27.
[4] Boni C,Fisicaro P,Valdatta C,et al.Characterization of hepatitis b virus(HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81(8):4215-4225.
[5] Gonzalez E,Kulkarni H,Bolivar H,et al.The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science,2005,307(5714):1434-1440.
[6] Shiow LR,Paris K,Akana MC,et al.Severe combined immunodeficiency(SCID) and attention deficit hyperactivity disorder (ADHD) associated with a coronin-1A mutation and a chromosome 16p11.2 deletion. Clin Immunol,2009,131(1):24-30.
[7] Fanciulli M,Norsworthy PJ,Petretto E,et al.FCGR3B copy number variation is associated with susceptibility to systemic,but not organ-specific,autoimmunity. Nat Genet,2007,399(6):721-723.
[8] Grayson BL,Smith ME,Thomas JW,et al.Genome-wide analysis of copy number variation in type 1 diabetes. PLoS One,2010,5(11):e15393.
[9] Shostakovich-Koretskaya L,Catano G,Chykarenko ZA,et al.Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS,2009,23(6):679-688.
[10] Swaminathan S,Kim S,Shen L,et al.Genomic copy number analysis in alzheimer's disease and mild cognitive impairment:an andi study. Int J Alzheimers Dis,2011,2011(2011):729478.
[11] Chen L,Zhang Z,Chen W,et al.B7-H1 up-regulation on myeloid dendritic cells significantly suppresses t cell immune function in patients with chronic hepatitis B. J Immunol,2007,178(10):6634-6641.
[12] Chen J,Wang XM,Wu XJ,et al.Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res,2011,60(1):47-53.
[13] Du R,Lu C,Jiang Z,et al.Efficient typing of copy number variations in a segmental duplication-mediated rearrangement hotspot using multiplex competitive amplification. J Hum Genet,2012,57(8):545-551.
[14] Zinn-Justin J.Cutting edge:programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+T cells in acute self-limited hepatitis B virus infection. J Immunol,2008,181(6):3741-3744.
[15] Muenst S,Soysal S D,Tzankov A,et al.The PD-1/PD-L1 pathway:biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Therap Targ,2015,19(2):201.
[16] Michel ML,Deng Q,Mancini-Bourgine M.Therapeutic vaccines and immune—based therapies for the treatment of chronic hepatitis b:perspectives and challenges. J Hepatol,2011,54(6):1286-1296.
[17] Wu JF, Wu TC, Chen CH, et al.Serum levels of interleukin-10 and interleukin-12 predict early,spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology,2010,138(1):165-172.
[18] Stranger BE,Forrest MS,Dunning M,et al.Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science,2007,315(5813):848-853.
[19] 杨湛,吴令杰,范慧敏,等. 慢性乙型肝炎病毒感染者程序性死亡因子1基因拷贝数和mRNA的表达水平.中华肝脏病杂志,2011,19(9):678-682.
[20] 朱晓燕,胥萍,陈慧,等. 乙型肝炎肝硬化患者外周血T细胞PD-1和PD-L1水平及意义. 实用肝脏病杂志,2013,16(3):220-222.

不同HBV感染转归人群外周血PD-1拷贝数分布研究^*

Frequency of PD-1 copy number variation in individuals with hepatitis B viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[7]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[8]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[11]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.